AstraZeneca has been a driving force in CV science for more than 100 years and continues to be a pioneer in the industry, both with our current portfolio and innovation-rich pipeline. And so it’s with great excitement that we again have such a strong presence at this year’s ESC Congress in Barcelona, Spain, including data for patients with a history of heart attack.
At ESC 2017, we will not only be showcasing the positive impact of our medicines in the core CV disease areas as we know them, but will be showing how we are investing in the science to understand the progression of CV-related disease and identifying approaches to reduce CV risk.
Follow us on Twitter @AstraZeneca, and join the conversation #ESCCongress.
Veeva ID: Z4-6487
Date of next review: August 2018